These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Molecular basis of fibrin clot elasticity. Lim BB; Lee EH; Sotomayor M; Schulten K Structure; 2008 Mar; 16(3):449-59. PubMed ID: 18294856 [TBL] [Abstract][Full Text] [Related]
12. The elastic modulus of fibrin clots and fibrinogen gels: the effect of fibronectin and dithiothreitol. Procyk R; King RG Biopolymers; 1990 Feb; 29(3):559-65. PubMed ID: 1970486 [TBL] [Abstract][Full Text] [Related]
13. Gender-specific alterations in fibrin structure function in type 2 diabetes: associations with cardiometabolic and vascular markers. Alzahrani SH; Hess K; Price JF; Strachan M; Baxter PD; Cubbon R; Phoenix F; Gamlen T; Ariëns RA; Grant PJ; Ajjan RA J Clin Endocrinol Metab; 2012 Dec; 97(12):E2282-7. PubMed ID: 22996148 [TBL] [Abstract][Full Text] [Related]
14. Rheology of blood coagulation. Kaibara M Biorheology; 1996; 33(2):101-17. PubMed ID: 8679959 [TBL] [Abstract][Full Text] [Related]
15. Distribution of alpha-polymers and residual alpha-chains in in vitro and in vivo formed fibrin clots. Barthels M; Förstermann U; Sosada M; Poliwoda H Behring Inst Mitt; 1986 Feb; (79):24-30. PubMed ID: 3718409 [TBL] [Abstract][Full Text] [Related]
16. Altered fibrin clot properties in patients on long-term haemodialysis: relation to cardiovascular mortality. Undas A; Kolarz M; Kopeć G; Tracz W Nephrol Dial Transplant; 2008 Jun; 23(6):2010-5. PubMed ID: 18156458 [TBL] [Abstract][Full Text] [Related]
17. [Fibrinogen, a vascular risk factor]. Caen JP; Soria J; Collet JP; Soria C Bull Acad Natl Med; 1993 Nov; 177(8):1433-41; discussion 1441-4. PubMed ID: 8193948 [TBL] [Abstract][Full Text] [Related]
18. [Spatial aspects of blood coagulation dynamics. III. Growth of clots in vitro]. Ataullakhanov FI; Volkova RI; Guriia GT; Sarbash VI Biofizika; 1995; 40(6):1320-8. PubMed ID: 8590724 [TBL] [Abstract][Full Text] [Related]
19. In vitro fibrin clot formation and fibrinolysis using heterozygous plasma fibrinogen from gammaAsn319, Asp320 deletion dysfibrinogen, Otsu I. Terasawa F; Kani S; Hongo M; Okumura N Thromb Res; 2006; 118(5):651-61. PubMed ID: 16412498 [TBL] [Abstract][Full Text] [Related]